Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02281929
Other study ID # 2014_05
Secondary ID 2014-002536-13PH
Status Completed
Phase Phase 3
First received
Last updated
Start date June 13, 2015
Est. completion date November 19, 2019

Study information

Verified date March 2021
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Treatment of reference of severe alcoholic hepatitis is based on corticosteroids, given for 28 days. However, about 25-35% of patients do not take benefit from this treatment and die within the 6 months following the diagnosis. Numerous trials have evaluated the impact of several strategies in association with corticosteroids. None of them has shown an improvement in survival (primary endpoint) as compared to corticosteroids alone. The project is based on an approach never tested in a randomized controlled trial in severe alcoholic hepatitis, targeting the group of patients at high risk of death (25-35% at 2 months). This approach is based on animal and human studies.Antibiotics are effective in animal models and in other circumstances characterized by liver failure such as gastrointestinal bleeding related to portal hypertension. The interest of studying this population is emphasized by the frequency of infections in these critically ill patients. Antibiotics will be administered before the development of any infection, as it is likely that these patients present with mesenteric bacterial adenitis without systemic signs of infection. Primary endpoint will be 2-month survival as most deaths occur within 60 days and treatment is given for 30 days.


Description:

This is a multicenter double-blind randomized controlled study on two parallel groups. Once inclusion and exclusion criteria verified and after having obtained patient written consent, participative centers will process to inclusion in the trial. Corticosteroids as well as antibiotics or their placebo will be started orally. Patients will be managed in the hospital unit until day 7, which corresponds to the evaluation of response to treatment using the Lille model. After this 7-day period, patients will be followed-up at day 14, day 21, day 30, day 60 (primary endpoint). During each visit, biological and clinical features including efficacy and tolerance will be assessed as well as presence of infection and hepatorenal syndrome (secondary endpoints).


Recruitment information / eligibility

Status Completed
Enrollment 297
Est. completion date November 19, 2019
Est. primary completion date November 19, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients aged 18-75 - Recent onset of jaundice (<3 months) - Biopsy proven alcoholic hepatitis (transjugular liver biopsy) - Maddrey's discriminant function = 32, defining severe alcoholic hepatitis - MELD score =21 - Alcohol consumption = 40g/day (women) and = 50g/day (men) - Written informed consent Exclusion Criteria: - Previous severe allergy or hypersensitivity to amoxicillin or clavulanic acid (anaphylactic shock, Quincke edema, severe urticaria) - Hypersensitivity to any component of the medication - History of liver injury to amoxicillin and/or clavulanic acid - Phenylketonuria, because of the presence of aspartame in the powder for the oral suspension - Type 1 hepatorenal syndrome before the initiation of treatment - Severe extrahepatic disease - Any malignant tumor < 2 years - Uncontrolled gastrointestinal bleeding - Ongoing viral or parasitic infection - Untreated bacterial infection.

Study Design


Intervention

Drug:
Amoxicillin
Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
Placebo
Placebo in three daily doses during 30 days
Prednisolone
Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days

Locations

Country Name City State
France CHU d'Amiens Amiens
France CHU Angers
France CHU de Besançon Besançon
France Hôpital Jean Verdier (AH-HP) Bondy
France CHU de Caen Caen
France Hôpital BEaujon (AP-HP) Clichy
France Centre hospitalier Dunkerque
France CHU Grenoble Grenoble
France Hôpital Claude Huriez, CHU Lille
France CHU Montpellier Montpellier
France CHU Nantes Nantes
France CHU Nice Nice
France Hôpital La Pitié (AP-HP) Paris
France Hôpital Saint Antoine (AP-HP) Paris
France CHU Poitiers Poitiers
France CHU Pontchaillou Rennes
France CHU Rouen
France CHU Toulouse
France Centre Hospitalier Valenciennes
France Hôpital Paul Brousse (AH-HP) Villejuif

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Lille Ministry of Health, France

Country where clinical trial is conducted

France, 

References & Publications (6)

Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54. — View Citation

Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009 Aug;137(2):541-8. doi: 10.1053/j.gastro.2009.04.062. Epub 2009 May 13. — View Citation

Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009 Jun 25;360(26):2758-69. doi: 10.1056/NEJMra0805786. Review. — View Citation

Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013 Sep 11;310(10):1033-41. doi: 10.1001/jama.2013.276300. — View Citation

Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. doi: 10.1136/gut.2010.224097. Epub 2010 Oct 12. — View Citation

Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9. doi: 10.1056/NEJMoa1101214. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Patient alive The percentage of patients alive at 2 months in the experimental arm compared to the percentage of patients alive in the control arm at day 60
Secondary Infection incidence of infection over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm at day 7, day14, day 21, day 30, day 60; at 3 months, at 6 months
Secondary Hepatorenal syndrome incidence of hepatorenal syndrome over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm at day 7, day14, day 21, day 30,at 3 months, at 6 months
Secondary MELD score <17 percentage of patients with a low risk of mortality during the first two months (assessed by a MELD score <17) in the two arms of treatment. The MELD score will be calculated using the following formula:(9.57 × log creatinine in milligrams per deciliter) + (3.78 × log bilirubin in milligrams per deciliter) + (11.20 × log international normalized ratio) + 6.43. at day 7, day14, day 21, day 30,
Secondary Lille Model percentage of patients disclosing a response to treatment assessed by the Lille model (<0.45) in the two arms of treatment. at day 7, after the first administration of treatment
Secondary Patient alive The percentage of patients alive at 2 months in the experimental arm compared to the percentage of patients alive in the control arm at 3 months, at 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04066179 - Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients. N/A
Completed NCT03732586 - Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT00962442 - N-Acetylcysteine in Severe Acute Alcoholic Hepatitis Phase 3
Not yet recruiting NCT06307522 - MRG-001 in Patients With Alcoholic Hepatitis Phase 2
Recruiting NCT05018481 - HA35 Moderate Alcoholic Hepatitis (AH) Study Early Phase 1
Completed NCT04544020 - Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Recruiting NCT04088370 - Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Completed NCT04235855 - EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication? N/A
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT00851981 - Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease Phase 2
Completed NCT04084522 - Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis N/A
Completed NCT05840640 - Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis Phase 4
Recruiting NCT03069300 - N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis Phase 3
Terminated NCT02039219 - Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Phase 2
Completed NCT02019056 - Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Phase 2
Completed NCT01245257 - Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis N/A
Completed NCT00388323 - Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human N/A
Recruiting NCT03845205 - Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH N/A
Recruiting NCT03703674 - GCSF in Alcoholic Hepatitis Phase 4

External Links